IL239008A0 - Peptides that stimulate the formation of subcutaneous fat cells - Google Patents

Peptides that stimulate the formation of subcutaneous fat cells

Info

Publication number
IL239008A0
IL239008A0 IL239008A IL23900815A IL239008A0 IL 239008 A0 IL239008 A0 IL 239008A0 IL 239008 A IL239008 A IL 239008A IL 23900815 A IL23900815 A IL 23900815A IL 239008 A0 IL239008 A0 IL 239008A0
Authority
IL
Israel
Prior art keywords
peptides
subcutaneous adipogenesis
stimulate subcutaneous
stimulate
adipogenesis
Prior art date
Application number
IL239008A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ California
Eva A Turley
Seyed Bahram Bahrami
Mina J Bissell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Eva A Turley, Seyed Bahram Bahrami, Mina J Bissell filed Critical Univ California
Publication of IL239008A0 publication Critical patent/IL239008A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
IL239008A 2012-11-25 2015-05-25 Peptides that stimulate the formation of subcutaneous fat cells IL239008A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261729626P 2012-11-25 2012-11-25
US201361778084P 2013-03-12 2013-03-12
PCT/US2013/071719 WO2014082042A2 (en) 2012-11-25 2013-11-25 Peptides that stimulate subcutaneous adipogenesis

Publications (1)

Publication Number Publication Date
IL239008A0 true IL239008A0 (en) 2015-07-30

Family

ID=49753509

Family Applications (1)

Application Number Title Priority Date Filing Date
IL239008A IL239008A0 (en) 2012-11-25 2015-05-25 Peptides that stimulate the formation of subcutaneous fat cells

Country Status (11)

Country Link
US (2) US10766927B2 (enExample)
EP (1) EP2922869B1 (enExample)
JP (1) JP2016501866A (enExample)
KR (1) KR20150088841A (enExample)
CN (1) CN105008396A (enExample)
AU (1) AU2013347797A1 (enExample)
CA (1) CA2930117A1 (enExample)
HK (1) HK1216895A1 (enExample)
IL (1) IL239008A0 (enExample)
RU (1) RU2015123315A (enExample)
WO (1) WO2014082042A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1216895A1 (zh) 2012-11-25 2016-12-09 The Regents Of The University Of California 刺激皮下脂肪形成的肽
WO2015184125A1 (en) 2014-05-28 2015-12-03 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
US10562935B2 (en) 2015-03-20 2020-02-18 London Health Sciences Centre Research Inc. Stapled peptides and uses thereof
CN107771085B (zh) * 2015-04-17 2024-09-03 斯米克控股(美国)有限公司 生物缀合物及其用途
KR102208853B1 (ko) * 2018-05-08 2021-01-28 오션펩 주식회사 주름개선 효능을 갖는 펩티드
CN113164512A (zh) * 2018-11-26 2021-07-23 韩国海洋科学技术院 刺激脂肪生成的肽、组合物和方法
CN114081861B (zh) * 2021-11-19 2023-10-31 和泓尚医(成都)生物科技有限公司 一种干细胞外泌体与复合肽抗衰制剂及其制备方法和应用
GB202211043D0 (en) * 2022-07-28 2022-09-14 Univ Birmingham Peptide agonist
WO2025059165A1 (en) * 2023-09-14 2025-03-20 University Of Florida Research Foundation, Incorporated Methods of use for rhamm-derived peptides and rhamm-derived peptide mimetics

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA175473A (en) * 1917-01-08 1917-03-06 Clarence G. Cashman Reamer head
GB9207949D0 (en) 1992-04-09 1992-05-27 Univ Manitoba Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
WO1994016328A1 (en) 1992-12-30 1994-07-21 Matthias Rath Synthetic oligopeptides analogous to protein signal sequences methods of identification and methods of use
GB9420740D0 (en) 1994-10-14 1994-11-30 Univ Manitoba Sequence of the hyaluronan receptor gene
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
CA2166155C (en) 1995-12-27 2008-02-05 Eva Anne Turley Agents binding to hyaluronic acid binding domains and the use thereof
GB9607441D0 (en) 1996-04-10 1996-06-12 Univ Manitoba Human hyaluronan receptor
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
CA2237051A1 (en) 1997-12-19 1999-06-19 Eva A. Turley Enhanced affinity hyaluronan binding peptides
US6211149B1 (en) 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
GB9811962D0 (en) 1998-06-03 1998-07-29 Janssen Pharmaceutica Nv Vertebrate homologue of UNC-53 protein of C.elegans
EP1151012A4 (en) 1998-11-19 2003-01-08 Smithkline Beecham Corp ANTAGONIST ANTIBODIES OF RHAMM
US6153432A (en) 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
JP2000217576A (ja) 1999-02-02 2000-08-08 Herikkusu Kenkyusho:Kk 脂肪細胞への分化を誘導する方法、並びに脂肪細胞への分化を制御する化合物およびそのスクリーニング方法
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20070116669A1 (en) * 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
WO2001080899A2 (en) 2000-04-20 2001-11-01 Cangene Corporation Rhamm peptide conjugates
US7601825B2 (en) 2001-03-05 2009-10-13 Agensys, Inc. Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
EP1401483A1 (en) 2001-06-11 2004-03-31 Transition Therapeutics Inc. Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
EP1407039A4 (en) * 2001-06-19 2005-12-21 Us Gov Health & Human Serv ANTI-ARTHROPODE VECTOR VACCINES, SELECTION METHOD AND USES THEREOF
US7387800B2 (en) 2001-08-15 2008-06-17 Meiji Dairies Corporation Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect
US20030170755A1 (en) 2001-09-26 2003-09-11 Ludwig Institute For Cancer Research Tumor-associated antigen RHAMM
AU2002332028A1 (en) 2001-10-06 2003-04-22 Boston Medical Center Corporation Preadipocyte cell strains and uses therefore
WO2003043998A1 (en) 2001-11-15 2003-05-30 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
WO2003048358A1 (fr) 2001-12-07 2003-06-12 Nissui Pharmaceutical Co., Ltd. Gene et proteine associes a la differenciation adipocytaire
FR2834996B1 (fr) 2002-01-18 2004-12-03 Genfit S A Methode d'identification de substances capables de moduler la differenciation adipocytaire
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2004003545A1 (en) 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
AU2003259285A1 (en) 2002-07-29 2004-02-16 Hmgene, Inc. Methods of identifying adipocyte specific genes, the genes identified, and their uses
EP1620061B1 (en) * 2003-04-28 2010-02-24 Sequoia Pharmaceuticals, Inc. Antiviral agents for the treatment, control and prevention of infections by coronaviruses
US20040229219A1 (en) * 2003-04-30 2004-11-18 Gallaher William R. Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)
AU2004266642A1 (en) 2003-08-12 2005-03-03 University Of Utah Research Foundation Heparin binding proteins: sensors for heparin detection
EP1677735B1 (en) 2003-10-17 2014-07-23 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7544661B2 (en) 2003-12-05 2009-06-09 Northwestern University Self-assembling peptide amphiphiles and related methods for growth factor delivery
CA2610791C (en) 2005-06-08 2015-12-01 Cangene Corporation Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
US20090176306A1 (en) 2005-06-10 2009-07-09 Toshio Taira Method of inducing differentiation from visceral preadipocyte to visceral adipocyte
US20070179085A1 (en) 2005-07-20 2007-08-02 Savani Rashmin C Modulation of rhamm-caveolin/lipid raft interactions to affect development, responses to tissue injury, angiogenesis, tumorigenesis, metastasis and growth factor/cytokine responses
US20070292869A1 (en) 2006-03-02 2007-12-20 Ppd Biomarker Discovery Sciences, Llc Compositions and Methods for Analyzing Renal Cancer
US8066691B2 (en) 2006-04-21 2011-11-29 Khouri Roger K Method and system for preparing soft tissue for grafting, enhancing grafting results, and grafting autologous fat to soft tissue such as the breast
WO2008047061A2 (fr) 2006-10-20 2008-04-24 Laboratoires Inneov Utilisation cosmetique par voie orale et/ou parenterale de la glucosamine eventuellement associee a au moins un compose polyphenol et composition correspondante
CA2670320A1 (en) 2006-11-21 2008-11-20 The Regents Of The University Of California Modulation of rhamm (cd168) for selective adipose tissue development
US20100062000A1 (en) 2006-11-21 2010-03-11 The Regents Of The University Of California Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
EP1967524A1 (en) * 2007-03-06 2008-09-10 Friesland Brands B.V. Methods for producing ACE-inhibitory peptides from whey and peptides obtained thereby
WO2009036246A2 (en) 2007-09-14 2009-03-19 Immunotope, Inc. Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US20100290989A1 (en) 2007-10-12 2010-11-18 London Health Sciences Centre Research Inc. Compositions affecting hyaluronic acid mediated activity
WO2009061130A2 (en) 2007-11-06 2009-05-14 Procell Therapeutics Inc. Cell permeable runx3 recombinant proteins, polynucleotides encoding the same, and anticancer compositions including the same
US8216828B2 (en) 2008-05-30 2012-07-10 Corning Incorporated Assembly of cell culture vessels
EP2576597A4 (en) 2010-05-31 2013-11-06 London Health Sci Ct Res Inc HYALURONIC ACID MEDIATED MOTILITY RECEPTOR BINDING PEPTIDES (RHAMM)
US20120076810A1 (en) 2010-09-01 2012-03-29 Poland Gregory A Vaccinia virus polypeptides
CA2809847A1 (en) 2010-09-01 2012-03-08 The Regents Of The University Of California Cell culture screen for agents that control adipogenesis and myofibroblast differentiation
MX2013002303A (es) * 2010-09-07 2013-10-28 Oncotherapy Science Inc Peptidos hjurp y vacunas que incluyen los mismos.
HK1216895A1 (zh) 2012-11-25 2016-12-09 The Regents Of The University Of California 刺激皮下脂肪形成的肽
WO2015184125A1 (en) 2014-05-28 2015-12-03 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis

Also Published As

Publication number Publication date
WO2014082042A2 (en) 2014-05-30
EP2922869B1 (en) 2017-09-27
AU2013347797A1 (en) 2015-07-02
KR20150088841A (ko) 2015-08-03
US20140179616A1 (en) 2014-06-26
US10494402B2 (en) 2019-12-03
US20150284433A1 (en) 2015-10-08
CA2930117A1 (en) 2014-05-30
CN105008396A (zh) 2015-10-28
JP2016501866A (ja) 2016-01-21
US10766927B2 (en) 2020-09-08
EP2922869A2 (en) 2015-09-30
WO2014082042A3 (en) 2014-07-24
RU2015123315A (ru) 2017-01-10
HK1216895A1 (zh) 2016-12-09

Similar Documents

Publication Publication Date Title
IL245744A0 (en) Therapeutic peptides
SG11201506766PA (en) Therapeutic peptides
GB2501897B (en) Injection devices
SG11201508469YA (en) Therapeutic peptides
IL231604B (en) Therapeutic peptides
DK2623146T3 (en) Injection devices
EP2857033A4 (en) PEPTIDE WITH SKIN PERMEATION
IL239008A0 (en) Peptides that stimulate the formation of subcutaneous fat cells
GB201217439D0 (en) Combination therapy
GB201219753D0 (en) Injection devices
PL2662073T3 (pl) Wstrzykiwanie oktreotydu
GB201207305D0 (en) Therapy
SI2890785T1 (sl) PCSK9 peptidno cepivo
ZA201503127B (en) Peptides
GB201200555D0 (en) Peptide
EP2879707A4 (en) COMBINATION THERAPY
GB201204868D0 (en) Peptides
EP2804853A4 (en) THERAPEUTIC USES
PT2891663T (pt) Péptidos derivados de psf1
GB201308860D0 (en) Delivery peptides
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
GB201221414D0 (en) Trans-locating peptide
GB201207895D0 (en) Peptides
GB201200509D0 (en) Peptides